What Is the Best Strategy for Moderately Complex Femoropopliteal Lesions?

At present, PCI is the preferred treatment for femoropopliteal lesions and drug coated balloons (DCB) have shown good performance. However, they have not yet been shown superior to bare-metal stents (BMS). 

¿Cuál es la mejor estrategia en el territorio femoropoplíteo en lesiones de moderada complejidad?

This study compared randomized trials IN.PACT SFA I/II and IN.PACT JAPAN including 288 patients vs. the prospective Complete SE and DURABILITY II with 483 analyzed patients.

Final efficacy end point was primary patency defined as clinically driven target lesion revascularization (TLR) or freedom from restenosis at 12 months.

The populations were similar, mean age was 68, 65% were men, 90% presented hypertension, 40% diabetes, 6% required insulin, 34% were smokers and 50% had heart disease.

96% were in Rutherford 2-3 functional class. In 96% of cases, the superficial femoral was treated, 2.5% the popliteal, and 1.5% both. Lesion length was 80 mm, 33% were total occlusions and residual restenosis was higher in DCB patients (20% vs. 17.1% p<0.01). 

Read also: TAVR and New Onset LBBB.

Primary end point of efficacy resulted in favor of DCB (90.4% DCB vs. 80.9% BMS, P= 0.007). At 36 months, freedom for ischemia driven TLR also resulted in favor of DCB (85.6% DCB, 73.7% BMS, P= 0.001), as was MAE (25.3% DCB, 38.8% BMS, P < 0.001).

There were no differences at 3 years in all-cause mortality, major amputation or stent thrombosis. 

Conclusion

In this group of patients (based on the adjusted analysis of patients pooled from different studies) drug coated balloons showed better patency, lower need for revascularization and lower MAE rates, with no statistical difference in mortality, amputation or stent thrombosis, compared against conventional bare metal stents. This analysis supports the use of drug coated balloons in moderately complex lesions in femoropopliteal territory, where both strategies are viable. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Original Title: Comparison of Drug-Coated Balloons vs Bare-Metal Stents in Patients With Femoropopliteal Arterial Disease.

Reference: Mehdi H. Shishehbor, et al. J Am Coll Cardiol 2023;81:237–249.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...